Novel Peptides: An Alternative Approach for the Treatment of Diabetes Mellitus

Authors: Ghosh, Rumi; Thanawala, Vaidehi; Kadam, Vilasrao J.

Source: Current Drug Therapy, Volume 2, Number 3, September 2007 , pp. 196-204(9)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $62.88 plus tax (Refund Policy)

Abstract:

With the alarming increase in the incidence of diabetes mellitus worldwide, there is a growing need to develop new strategies to control hyperglycemia. Currently available treatments cause various adverse effects and do not necessarily achieve optimal glycemic control. Recently, peptides that may ameliorate the symptoms of diabetes mellitus have been investigated extensively and show great promise. Synthetic analogs of amylin and incretin mimetics may be ideal adjuncts to diabetes therapy. Amylin analogs significantly improve postprandial control in patients with either type 1 or type 2 diabetes without an increased risk of hypoglycemia or weight gain. Incretin mimetics are a new option for patients suffering from type 2 diabetes and are being considered as a stand-alone therapy. The present paper reviews novel peptides as potential agents for glucose control and prevention of the complications associated with diabetes.

Keywords: Diabetes mellitus; peptides; alternatives

Document Type: Research article

DOI: http://dx.doi.org/10.2174/157488507781695658

Publication date: 2007-09-01

More about this publication?

Current Drug Therapy publishes frontier reviews on all the latest advances in drug therapy. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: new and existing drugs, therapies and medical devices.

The journal is essential reading for all researchers and clinicians involved in drug therapy.